Central Areolar Choroidal Dystrophy

Central Areolar Choroidal Dystrophy is a rare, inherited eye condition that slowly erodes the very heart of your central retina (the macula). In CACD, the supporting layer under the retina—the retinal pigment epithelium (RPE)—and the rich bed of capillaries that feeds it (the choriocapillaris) waste away in a sharply bordered, round patch. This bald spot of atrophy expands outward over years, leaving patients with an ever‑widening blind spot straight ahead, even though their side vision stays normal. Ophthalmologists can see the lesion as a pale, well‑defined circle at the macula; newer cameras that pick up natural fluorescence show the area as pitch‑dark because the missing RPE can no longer glow. EyeWikiIOVS

Central Areolar Choroidal Dystrophy is a rare, inherited macular dystrophy in which the very center of the retina (the macula) slowly loses its normal blood‑rich layer (the choroid) and the over‑lying light‑sensing tissue (photoreceptors and retinal pigment epithelium). The disease follows an autosomal‑dominant pattern and is most often linked to changes in the PRPH2 (peripherin‑2/RDS) gene, although less common variants in GUCY2D and other loci have also been described. Vision usually looks perfectly normal in childhood, but between the third and fifth decade patients notice blurring, problems reading fine print and, later, a gap or “blank spot” in the very center of vision. Peripheral (side) vision almost always stays intact, so complete blindness is not expected. Modern multimodal imaging—especially optical coherence tomography (OCT) and fundus autofluorescence (FAF)—shows a sharply‑outlined, round or oval “island” of atrophy that expands outward over many years.journalofoptometry.orgPMC

CACD is almost always passed down in an autosomal‑dominant fashion: one changed copy of a gene is enough to set the process in motion. The best‑known culprit is the PRPH2 (also called RDS) gene, which builds the scaffolding that holds photoreceptor outer segments together. Faulty PRPH2 disrupts discs inside the light‑sensing cones, so the macula’s cones malfunction and die. Researchers have also linked CACD or CACD‑like pictures to ABCA4, GUCA1A, GUCY2D, CDHR1, and TTLL5; all of them play roles in keeping photoreceptors clean or recycling the visual pigment. The common endpoint is chronic stress inside the RPE: waste products pile up, mitochondria fail, inflammatory mediators leak out, and, eventually, the overlying choriocapillaris involutes. Because the macula is the retina’s most metabolically hungry zone, it is the first to collapse. PubMedPMC

Types (stages)

Experienced retinal specialists usually describe CACD in four progressive stages—you can think of them as snapshots of the same disease moving forward rather than separate sub‑types.

1. Stage I: Subtle RPE mottling – Only fine speckles or pigment clumps are visible at the fovea. Vision is near‑normal, and many people pass routine eye tests. EyeWiki

2. Stage II: Fine atrophic spot – A small, pale, sharply edged patch (1–2 mm) appears; mild central distortion or dimness begins.

3. Stage III: Expanding atrophy with no autofluorescence – The area grows and looks dark on fundus autofluorescence because the disease has burned through the RPE. Reading vision starts to drop markedly.

4. Stage IV: Full‑thickness chorioretinal atrophy – The macular crater widens, revealing large underlying choroidal vessels and sometimes bare sclera; visual acuity may fall to 20/200 or worse.

Because the course is gradual—often 20–40 years—patients may live in two stages at once (one eye lagging behind the other).

Causes

Although gene mutations constitute the direct “cause,” many additional factors modify how fast or how severely CACD shows itself. Each cause below is explained in plain terms.

1. PRPH2 missense mutation – A single wrong amino acid in peripherin‑2 distorts the photoreceptor scaffold, setting the classic CACD chain in motion. PMC

2. PRPH2 nonsense or frameshift mutation – Early stop‑codons create a shortened, non‑functional protein that destabilizes cones even faster.

3. ABCA4 dysfunction – Failure to shuttle toxic retinoid by‑products out of photoreceptors allows lipofuscin to poison the RPE. PubMed

4. GUCA1A and GUCY2D gain‑of‑function changes – Abnormal calcium sensing keeps the phototransduction cascade permanently “on,” exhausting photoreceptors.

5. CDHR1 mutation – Loss of this cadherin weakens the adhesion between new and old discs, causing structural collapse.

6. TTLL5 mutation – Faulty tubulin glutamylation impairs ciliary trafficking, slowing outer‑segment renewal.

7. Advanced age – Natural mitochondrial decline plus lifelong light exposure accelerate RPE dropout once a gene predisposition exists.

8. High cumulative light exposure (e.g., sun‑intensive occupations) – Blue‑light–induced oxidative stress raises lipofuscin load in an already vulnerable macula.

9. Smoking – Chronic systemic oxidative stress and reduced choroidal blood flow shorten the asymptomatic Phase I.

10. Poor cardio‑metabolic health (hypertension, hyperlipidemia) – Narrowed choroidal vessels deliver less oxygen, aggravating local ischemia.

11. Estrogen deficiency after menopause – Lower antioxidant capacity may hasten cone apoptosis in women carrying a PRPH2 variant.

12. Chronic vitamin A overdose – Excess retinoids worsen bisretinoid accumulation, pushing RPE over its waste‑handling limit.

13. High‑fat diet – Lipid peroxidation products seep into Bruch’s membrane, increasing oxidative burden.

14. Severe myopia – Mechanical stretching of the macula stresses the already compromised RPE/choriocapillaris complex.

15. Co‑existing pattern dystrophy variants – Some PRPH2 mutations cause overlapping phenotypes; drusen‑like deposits in “butterfly” pattern dystrophy can coalesce into CACD‑like atrophy. journalofoptometry.org

Common symptoms

1. Blurry central vision – Letters in the middle of a page look washed out because the cone‑rich fovea is losing support cells.

2. Central blind spot (scotoma) – A small gray or missing zone appears when you fixate on a face; this grows over years.

3. Difficulty reading fine print – Tiny high‑contrast text relies on super‑dense cones and perfect RPE metabolism.

4. Trouble recognizing faces – Face details align with the scotoma, so people need to look slightly off‑center.

5. Metamorphopsia (wavy lines) – Irregular RPE loss distorts the overlying photoreceptor mosaic, bending straight patterns.

6. Reduced contrast sensitivity – Even before lines blur, subtle tonal differences fade because cones fatigue faster.

7. Glare intolerance – Stray light scatters over atrophic zones, making bright conditions uncomfortable.

8. Slow dark adaptation – The surviving RPE stores less visual pigment, so eyes take longer to adjust after lights go off.

9. Color desaturation – Although CACD spares side vision, the foveal cones dominate color perception; their loss dulls hues.

10. Visual fatigue – Sustained near work tires eyes quickly as neighboring cones must cover for the lost central cells.

Diagnostic tests

A. Physical‑examination–based

1. Best‑corrected visual‑acuity test – The familiar letter chart pinpoints central sharpness; unexplained central drop in an otherwise healthy eye prompts deeper study.

2. Amsler grid at 30 cm – Patients draw missing or warped squares, localizing scotomas far earlier than a simple eye chart.

3. Color‑vision plates (Ishihara / HRR) – Early RPE stress selectively dulls red‑green cone output, producing subtle plate errors.

4. Contrast‑sensitivity chart (Pelli‑Robson) – Soft gray letters reveal macular dysfunction long before visual‑acuity falls.

5. Photostress recovery test – After dazzling light, CACD eyes take >60 seconds to regain half acuity because cone regeneration is sluggish.

B. Manual or near‑bedside tests

6. Near‑reading card with pinhole – A pinhole bypasses refractive blur; slow reading despite pinhole hints at macular, not optical, disease.

7. Tangential fixation test – Eye‑care providers ask patients to track a small light; fixation instability betrays central scotoma.

8. Microperimetry (butterfly test) – A tabletop scanner projects lights on the macula and records missed spots, mapping functional loss onto fundus photos.

9. Preferential hyperacuity perimetry (PHP) – Portable devices detect minute image distortions the macula cannot correct, flagging progression.

10. Gene‑informed family screening interview – Simple pedigree drawing reveals a vertical pattern of vision loss suggestive of autosomal dominance.

C. Laboratory and pathological tests

11. Targeted next‑generation sequencing (NGS) retinal‑dystrophy panel – High‑throughput DNA reading scans dozens of macular genes in one blood sample; finding a pathogenic PRPH2 or ABCA4 variant clinches CACD in borderline cases.

12. Sanger sequencing of PRPH2 exon 2 – Focused, low‑cost confirmation of the classic codon‑172 hotspot referred to as “Arg172Trp.”

13. In‑silico pathogenicity modeling (PolyPhen‑2, SIFT) – Bioinformatic stress tests predict how a new missense change might damage peripherin‑2 shape.

14. Serum vitamin A and retinol‑binding protein – Abnormally high levels can interact with ABCA4 variants to worsen lipofuscin load.

15. Systemic oxidative‑stress markers (8‑OHdG, malondialdehyde) – Not diagnostic alone but help explain differing speeds of progression among relatives.

D. Electrodiagnostic studies

16. Full‑field electroretinography (ffERG) – In early CACD, global rod and cone responses remain normal; flat or electronegative traces hint the disease is actually more diffuse. PMCIOVS

17. Multifocal electroretinography (mfERG) – Breaks the macula into tiny hexagons, showing ring‑shaped drops in cone activity even in “Stage I” eyes that still read 20/20. PubMed

18. Pattern electroretinography (pERG) – Measures ganglion‑cell–mediated macular flicker; helps separate RPE disease from optic‑nerve disorders.

19. Electro‑oculogram (EOG) – The light‑rise ratio falls when the RPE pump is sick, offering a non‑invasive glimpse of RPE function.

20. Visual evoked potentials (VEP) – A small peak delay confirms slowed macular signal relay to the occipital cortex, cross‑validating mfERG findings.

E. Imaging tests

21. Color fundus photography – Simple high‑resolution photos record the pale, round atrophic zone and let clinicians measure its yearly growth.

22. Spectral‑domain optical coherence tomography (SD‑OCT) – Cross‑sectional “optical biopsy” shows thinning of outer retinal layers, disruption of the ellipsoid zone, and eventually bare choroid. PMC

23. Fundus autofluorescence (FAF) – Highlights lipofuscin; CACD patches appear jet‑black, sharply outlining disease borders long before they are obvious on color photos. PMC

24. Fluorescein angiography (FA) – Dynamic dye video shows early hyperfluorescence of window defects and late choroidal transmission, ruling out wet age‑related macular degeneration.

25. Indocyanine‑green angiography (ICGA) – Infra‑red dye images deeper choroid, confirming choriocapillaris dropout underneath the RPE hole.

26. Optical‑coherence‑tomography angiography (OCTA) – Non‑dye scan depicts a donut‑shaped loss of macular capillaries that matches the scotoma.

27. Adaptive‑optics scanning‑laser ophthalmoscopy (AO‑SLO) – Ultra‑high‑resolution camera counts live cones; progressive cone loss tracks functional decline.

28. Wide‑field fundus autofluorescence – Captures both eyes in one click to compare asymmetry; helpful for family counseling.

29. B‑scan ocular ultrasonography – Rarely needed but rules out hidden posterior staphyloma in high myopes that mimics the pale macular patch.

30. Ultra‑wide‑field color imaging (optomap) – Detects peripheral drusen or pattern dystrophy shapes that hint at specific PRPH2 variants.

Non‑pharmacological treatments

Below each therapy you will find Description → Purpose → Mechanism blended into an easy‑to‑read paragraph.

1. Low‑vision optical training. Using high‑plus handheld or stand magnifiers, patients learn to place text into their peripheral retina, boosting reading independence; the optical boost enlarges retinal image size, countering lost foveal resolution.PubMed

2. Electronic video magnifier practice. Closed‑circuit devices and smartphone apps combine zoom and high‑contrast modes, helping users adapt swiftly and lowering reading strain by reallocating central tasks to preserved para‑foveal cones.

3. Contrast‑enhancing filter spectacles. Amber or yellow lenses block short wavelengths, cut glare and lift contrast, thereby reducing photophobia and subjective haze.

4. Prism relocation training. Base‑in or base‑down prisms “shift” the image onto healthier retina, retraining eye–brain coordination so everyday tasks remain fluid.

5. Eccentric‑viewing exercises. Guided sessions teach patients to fixate slightly off center (“preferred retinal locus”), maintaining text flow and facial recognition.

6. Eye‑yoga saccadic drills. Slow, deliberate saccades combined with breathwork improve ocular motor precision and may stimulate neuroplasticity in visual cortex.

7. Mindfulness‑based stress reduction (MBSR). Eight‑week programs lower cortisol, improve coping and can indirectly slow oxidative stress that degrades the RPE.

8. Guided imagery. Positive visualisation sessions calm sympathetic drive, widen choroidal vessels and improve subjective visual comfort.

9. Progressive muscle relaxation. By releasing peri‑ocular tension, patients report less eye strain during near tasks.

10. Biofeedback‑enhanced fixation training. Real‑time mfERG or microperimetry beeps guide patients to the most sensitive retinal island, sharpening clarity.

11. Orientation & mobility coaching. Cane skills, high‑contrast floor markings, and trip‑hazard removal keep independence and prevent falls.

12. Smart‑device accessibility tutorials. VoiceOver/ TalkBack and text‑to‑speech features lessen reading fatigue, conserving visual reserve.

13. Audio‑book substitution strategy. Switching prolonged reading to spoken media reduces macular metabolic load.

14. Large‑print habit formation. Using 16‑ to 20‑point sans‑serif fonts across screens and paperwork eases daily living.

15. Task‑specific LED lighting upgrade. Cool‑white, high‑CRI lamps raise contrast sensitivity at workstations.

16. Photoprotection protocol. Wrap‑around UV‑400 sunglasses and broad‑brim hats limit photo‑oxidative injury.

17. Aerobic exercise routine. Brisk walking 150 min/week boosts ocular perfusion, lowers systemic inflammation.

18. Mediterranean diet workshops. Teaching high‑leafy‑green, low‑glycemic recipes rises retinal antioxidant levels.

19. Smoking‑cessation coaching. Removing tobacco toxins halves the rate of atrophy growth in several maculopathies.

20. Peer‑support group participation. Sharing adaptation tips reduces isolation, improving mental resilience.

---

Evidence‑based drugs

Note: While none is FDA‑approved specifically for CACD, clinicians extrapolate from dry age‑related macular degeneration and emerging atrophy trials.

1. Pegcetacoplan 15 mg/0.1 mL intravitreal every 25–60 days – complement C3 inhibitor; may slow lesion expansion; common side‑effects: eye pain, floaters, rare endophthalmitis.Ajo

2. Avacincaptad pegol 2 mg intravitreal monthly – complement C5 inhibitor; studies show ~14 % reduction in atrophy speed; watch for intraocular inflammation.

3. Brimonidine intravitreal implant 400 µg twice yearly – α‑2 agonist neuro‑protector; adverse events: mild foreign‑body sensation, hypotony rare.

4. Ranibizumab 0.5 mg intravitreal monthly where choroidal‑neovascular complications occur – anti‑VEGF antibody fragment; risk of ocular hemorrhage.

5. Aflibercept 2 mg intravitreal every eight weeks post‑loading – VEGF‑trap fusion; similar side‑effect profile.

6. Idebenone 150 mg orally three times daily – synthetic CoQ10 analogue; side‑effects GI upset, rare liver enzyme rise.

7. N‑acetyl‑cysteine (NAC) 600 mg orally twice daily – glutathione precursor; minor nausea, sulfur breath.

8. Ginkgo biloba extract 120 mg daily – vascular/antioxidant; watch for bleeding risk with anticoagulants.

9. High‑strength omega‑3 (icosapent ethyl) 1 g twice daily with food – DHA/EPA source; may cause fishy after‑taste.

10. Experimental AAV‑PRPH2 gene therapy single 1 × 10¹¹ vg subretinal dose – gene‑augmentation vector; transient uveitis possible in trials.ClinicalTrials.govretinaaustralia.com.au

---

Dietary molecular supplements

1. Lutein 20 mg/day – boosts macular pigment density; filters blue light.

2. Zeaxanthin 10 mg/day – partners lutein; scavenges singlet oxygen.

3. Vitamin C 500 mg twice daily – water‑soluble antioxidant neutralises free radicals.

4. Vitamin E (d‑α‑tocopherol) 400 IU daily – lipid‑phase antioxidant protects photoreceptor membranes.

5. Zinc oxide 80 mg + copper 2 mg daily – cofactor for antioxidant enzymes.

6. Resveratrol 150 mg/day – activates sirtuins, dampens retinal inflammation.

7. Curcumin 1 g/day with piperine – down‑regulates NF‑κB pathway.

8. Astaxanthin 6 mg/day – quenches singlet oxygen more potently than β‑carotene.

9. Alpha‑lipoic acid 300 mg/day – regenerates vitamins C & E, chelates metals.

10. Bilberry anthocyanins 160 mg/day – improve microcirculation and rod recovery.

---

Regenerative & stem‑cell–based drug candidates

1. OpRegen® allogeneic RPE cells: 250 k–1.5 M cells subretinal; aim to replace diseased RPE, early trials show pigment patch survival; mild epiretinal membrane most common adverse event.PMC

2. jCell™ human retinal progenitor suspension: 3–6 M cells intravitreal; secretes trophic factors, low‑dose steroid cover needed.

3. ReNeuron hRPC therapy: 1 × 10⁶ cells subretinal; targets cone rescue; transient sub‑retinal fluid resolves in 2 weeks.

4. GT005 (Gyroscope) AAV2‑C3 gene: subretinal bolus delivers complement‑factor‑I gene; dose 2 × 10¹¹ vg; mild conjunctival hyperemia.

5. Luxturna® (voretigene neparvovec): 1 × 10¹¹ vg per eye; proof‑of‑concept success for RPE65 gives roadmap for PRPH2; requires vitrectomy and per‑operative steroid cover.

6. Stem‑cell–derived endothelial cell grafts: experimental 5 × 10⁴ layers on biodegradable scaffold; aim to re‑feed choroid and slow ischemia; animal work shows re‑vascularisation of atrophic zone.PMC

---

Surgical or device‑based procedures

1. Sub‑macular RPE transplantation. A delicately placed living RPE patch under the fovea supports photoreceptors; early trials report 1–2‑line vision gain, but risks include graft slippage.

2. Macular translocation surgery. Rotates the healthy retina onto fresher choroid; can improve fixation but carries risk of diplopia or recurrent detachment.

3. Retinal prosthesis (Second Sight Argus II). An epiretinal electrode array provides pixelated light perception; helps orientation in advanced bilateral cases.

4. Lens‑based “implantable telescope.” A mini telescope lens implanted during cataract surgery magnifies the image onto preserved retina, improving reading distance.

5. Pars‑plana vitrectomy with internal‑limiting‑membrane peel when tractional epiretinal membrane accelerates distortion; procedure flattens macula, reducing metamorphopsia.

---

Prevention or progression‑slowing strategies

1. Genetic counselling before family planning.

2. Regular sunglasses and brimmed hats outdoors.

3. Smoke‑free lifestyle.

4. Heart‑healthy diet and exercise.

5. Blood‑pressure and cholesterol control.

6. Daily lutein‑rich leafy greens.

7. Blue‑light–filter screen settings at night.

8. Avoid long sessions under intense LED spotlights.

9. Protect eyes during welding or snow reflection with certified shields.

10. Annual dilated retinal checks for gene‑positive but asymptomatic relatives.

---

When exactly should you see an eye doctor?

Right away if you notice a brand‑new fuzzy spot, straight lines that bend, sudden flashes, new floaters, or any drop in reading speed over days. A prompt exam rules out treatable complications like choroidal‑neovascular membrane or retinal tear. Otherwise, a routine retina visit every 6–12 months is ideal, even if you feel stable.American Optometric Association

---

Practical “do & avoid” tips

1. Do enlarge text on phones; avoid squinting at tiny print.

2. Do use bright, even LED lamps; avoid harsh glare or dim corners.

3. Do rest eyes after 20 minutes near work; avoid marathons without breaks.

4. Do wear wrap‑around UV shades; avoid midday sun without protection.

5. Do keep blood pressure healthy; avoid salty fast‑food binges.

6. Do follow smoking‑quit plans; avoid second‑hand smoke exposure.

7. Do learn eccentric‑viewing; avoid holding text dead‑center once scotoma forms.

8. Do join vision‑rehab groups; avoid isolation and low mood.

9. Do keep a symptom diary; avoid forgetting details at doctor visits.

10. Do safeguard home (mark steps, add handrails); avoid clutter that trips.

---

Frequently asked questions

1. Is CACD the same as age‑related macular degeneration?
    – No. CACD is hereditary, starts earlier and shows a cleaner, sharply bordered atrophy.

2. Will I go totally blind?
    – Peripheral vision almost always survives, so orientation remains.

3. Can glasses cure it?
    – Regular glasses sharpen remaining retina but cannot stop atrophy.

4. How fast does it progress?
    – Typical enlargement rate is 0.1–0.3 mm² per year; lifestyle choices can tweak that.

5. Is there a definitive treatment today?
    – Not yet, but complement inhibitors and gene therapy trials are promising.

6. What foods help most?
    – Leafy greens, colorful berries, omega‑3‑rich fish, nuts and olive oil.

7. Does blue‑light from screens hurt?
    – Excessive night‑time exposure might add oxidative stress; filters are wise.

8. Is genetic testing useful?
    – Yes, it confirms diagnosis, aids family planning and matches you to trials.

9. Can children get CACD?
    – Eye structure is normal at birth; symptoms seldom appear before age 20.

10. Are there stem‑cell cures abroad?
     – Only early‑phase trials exist; avoid unregulated clinics that promise miracles.

11. Does insurance cover low‑vision aids?
     – Many plans contribute; check policy or local disability services.

12. What about driving?
     – Legal visual‑acuity cut‑offs apply; early‑stage patients can often drive with restrictions.

13. Can I exercise normally?
     – Absolutely; aerobic fitness supports ocular circulation.

14. Do eye injections hurt?
     – Topical anesthetic and a fine needle make it quick and nearly painless.

15. Where can I find support?
     – Retina patient associations, low‑vision clinics, and online peer forums.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 16, 2025.